7.43. Analysis.
Comparison 7 Heterogeneity analyses, Outcome 43 Number of serious adverse events‐ number of basal doses (intermediate acting).
Comparison 7 Heterogeneity analyses, Outcome 43 Number of serious adverse events‐ number of basal doses (intermediate acting).